Akeso Inc. 康方生物(9926.HK)
Pharmaceutical ManufacturingView the employees at
Akeso Inc. 康方生物(9926.HK)-
Lei Ma Vice President, Head of Clinical Pharmacology at Akesobio
-
New York City Metropolitan Area
-
Rising Star
Wenjing Qin clinical research physician-
Rising Star
Rawan Dahbar, PMP PMP, Clinical Project Manager-
Sydney, New South Wales, Australia
-
Rising Star
Lona Gonzales Clinical Team Manager at Akeso, Inc. 康方生物医药有限公司-
Brisbane, Queensland, Australia
-
Rising Star
Overview
Akeso (HKEX: 09926) is a commercial-stage biopharmaceutical company committed to the discovery, development, manufacturing, and commercialization of innovative medicines with high unmet medical needs worldwide. Founded in 2012, the company has established a comprehensive in-house drug development platform (ACE Platform) and know-how, including R&D, clinical development, CMC (Chemistry, Manufacturing, and Controls), and commercialization capabilities. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 30 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease, and other major therapeutic areas. 17 assets have entered clinical stage. Leveraging in-house developed bispecific platform technology (“Tetrabody technology”), the company has advanced four potential first-in-class bispecific antibody drugs into market or clinical development, including cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), PD-1/LAG-3, and TIGIT/TGF-Beta bispecific antibodies. In June 2022, cadonilimab was approved by the NMPA and became the first commercialized PD-1 based bispecific drug globally. Another Akeso internally discovered and developed oncology product, penpulimab (a PD-1 antibody), was granted marketing approval in China in August 2021. Akeso is listed on the Main Board of the Stock Exchange of Hong Kong Limited.
-